Fosun International Receives ESG Excellence Award From Top 100 Hong Kong Listed Companies Research Centre
On 24 February 2023, the Hong Kong Listed Companies Development Summit 2022 and the 10th Top 100 Hong Kong Listed Companies Awards Ceremony,co-organized by the Top 100 Hong Kong Listed Companies Research Centre, Finet, etc., were held at Island Shangri-La, Hong Kong. Fosun International received the ESG Excellence Award from the Top 100 Hong Kong Listed Companies Research Centre.
Initiated in 2012, the Top 100 Hong Kong Listed Companies Awards aims to use accurate data and a series of scientific criteria to analyze and calculate various data of Hong Kong listed companies in the previous year so as toidentify well-developed listed companies on the Main Board of Hong Kong Stock Exchange with investment prospects. After ten years of development, the list of Top 100 Hong Kong Listed Companies has become an important window for investors to observe the Hong Kong stock market. Other recipients of the ESG Excellence Award this year include large blue-chip listed companies such as MTR Corporation, CLP Holdings, HK Electric, Hong Kong and China Gas, and New World Development.
Fosun’s remarkable ESG performance has been highly recognized by global professional institutions
In recent years, global investors have attached increasing importance to the ESGperformance of enterprises. Fosun International has also continued to promote ESG work and achieved impressive results.Its MSCI ESG rating wasAAand the Hang Seng Sustainability rating was A. Fosun International has been selected as a constituent stock of Hang Seng ESG 50 Index (top 50 large-to-mid cap) for two consecutive years and it has been included as a constituent stock of the Hang Seng Corporate Sustainability Benchmark Index for three consecutive years, which includes 96 Hong Kong-listed companies with the most outstanding performance in corporate sustainability (top 20% of the Hang Seng Composite Index constituent stocks). In 2022, Fosun International has been included in the FTSE4Good Index Series for the first time. Its S&P CSA ESG score ranked ahead of 91% of its global peers and significantly ahead of the industry average. All these affirmed Fosun's ESG achievement and the global recognition of Fosun's ESG efforts.
Fosun's two treasures, "drug + vaccine" demonstrate the Group's social responsibility contributions to the fight against the pandemic
The judging panel pointed out that since the COVID-19 outbreak in early 2020, Fosun immediately initiated the global deployment of medical supplies and has continued to contribute to the fight against the pandemic in China and overseas. Fosun also partnered with BioNTech, a German biotechnology company, to develop the COVID-19 mRNA vaccine (COMIRNATY®). Since 6 January 2023, the self-paid vaccination service for COMIRNATY® bivalent vaccine has been rolled out in Hong Kong SAR to offer more vaccine options for people in need; following the rollout of self-paid vaccination service of COMIRNATY® monovalent COVID-19 mRNA vaccine for non-local residents in Macao SAR last year, the COMIRNATY® bivalent vaccine was approved as a regular imported vaccine in Macao SAR in January 2023, and vaccination of the booster dose is now available to non-local residents including mainland residents.
The self-paid vaccination service for COMIRNATY® vaccine has been rolled out in Hong Kong SAR and Macao SAR, providing more vaccine options for people in need and helping to build a health protection barrier
Azvudine tablets is the first domestically developed small molecule oral medication for COVID-19. In July 2022, Fosun Pharma and Genuine Biotech entered into an agreement in relation to the strategic collaboration on the joint development and Fosun Pharma’s exclusive commercialization of Azvudine. The COVID-19 oral medication, Azvudine, is now included in the medical insurance scheme in 31 provinces, autonomous regions, and municipalities across the country and is now available in primary healthcare institutions in many provinces. In response to the infection peak season of COVID-19 in rural areas that may be brought about by people returning home during Chinese New Year, Fosun Foundation announced on 9 January 2023 the cooperation with Fosun Pharma and Genuine Biotech to donate RMB100 million worth of Azvudine, the oral medication for COVID-19, helping the grassroots to weather the epidemic.
Fosun Foundation partners with Fosun Pharma and Genuine Biotech to donate RMB100 million worth of Azvudine, the oral medication for COVID-19, helping the grassroots to weather the epidemic
Fosun has been adhering to its corporate value of "Self-improvement, Teamwork, Performance, and Contribution to Society" since its establishment. As a global enterprise rooted in China, while actively creating business value, Fosun attaches great importance to corporate social responsibility and incorporates social responsibility into its sustainable development strategy. In order to further fulfill its corporate social responsibility, Fosun established Fosun Foundation in 2012 and continues to advance in the fields of global emergency relief, rural revitalization, health, education, culture and art, and caring for children and adolescents, demonstrating its commitment to public welfare. In the future, Fosun will continue to develop its businesses, strengthen innovation and globalization, and join hands with customers, partners, investors and all parties in society to forge ahead and continue to uphold its original aspiration of “Contribution to Society” so as to actively promote the sustainable development of ESG globally to fulfil Fosun’s mission of “Creating Happier Lives for Families Worldwide”.